GRSF1 and breast carcinoma: Similarly, the aberrant expression pattern of GRSF1 and MAPT was also verified by immunohistochemical (IHC) staining in 48 clinical tissue samples (23 tamoxifen-resistant versus 25 tamoxifen-sensitive) collected from breast cancer patients receiving tamoxifen treatment in our hospital (GRSF1: P=0.009; MAPT: P=0.017, Figure 5B).